FT: Questions About $PFE's Paxlovid Pills

Financial Times headline: US pins faith on Pfizer’s ‘living with Covid’ pill

Sub-headline: The antiviral drug Paxlovid is being widely prescribed but there are questions about its effectiveness


Late last year it looked like a key to “living with Covid” had finally been found. Pfizer’s antiviral drug Paxlovid had been approved, giving the newly infected the option of popping a pill to tackle their symptoms, cutting hospitalisations and other damaging effects of the disease.

But new studies have raised significant questions about a drug that was even mentioned by US president Joe Biden in his annual State of the Union address.

These include how well it works in lower-risk patients, why some suffer Covid-19 “rebound” — symptoms returning after they stop taking the drug — and whether the virus could become resistant to it.

1 Like